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Identity 
Other names: DKFZp762O1912, FLJ14393, MDIG, 
MINA53, NO52 
HGNC (Hugo): MINA 
Location: 3q11.2 
Note: MINA (myc induced nuclear antigen) is a gene 
whose expression is directly induced by c-MYC 
protein. The MINA gene encodes a protein with a 
molecular weight of 53 kDa that is localized in the 
nucleoplasm and nucleolus. 
DNA/RNA 
Description 
The human MINA gene consists of twelve exons 
spanning a 30 kb. The translation start site locates in 
exon 2, which follows two distinct exons, exon 1a and 
exon 1b.  
Thus, there are two transcription initiation sites in the 
human MINA gene. The exon 1b exists 0.25 kb 
downstream of the exon 1a. The stop codon (TAG) 
exists in the last exon, exon 10. The open reading frame 
of the coding region is 1398 bp, encoding 465 amino 
acids. mRNA encoding 464 amino acids (lacking 
297Q) is also generated by alternative splicing due to 
the lack of the first three bp of exon 7. 
Transcription 
The human MINA coding sequence consists of 1398 bp 
from the start codon to the stop codon. In addition to 
the 1395 bp-coding sequence, multiple alternative 
spliced transcript variants have been found for this 
gene. c-MYC protein stimulates the transcription of 
MINA through the E-box near the transcription start 
sites (Tsuneoka et al., 2002). The expression of MINA 
is also induced by serum (Tsuneoka et al., 2002). 
 
a. Exon-intron structure of the MINA gene. There are two transcription initiation sites at exon 1a and exon 1b.  
b. mRNA for human MINA that encodes MINA protein. The protein is coded from exon 2 to exon 10. 
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Protein 
 
Structural features of MINA protein. The positions of the 
JmjC domain is shown (green). 
Description 
Structure: MINA is a member of the jumonji C (JmjC) 
protein family, and suspected to hydroxylate some 
proteins to control gene expression. 
Activation: The expression of mRNA is elevated by c-
MYC protein, and frequently increased in various types 
of cancers, including human colon cancer, esophageal 
squamous cell carcinoma (ESCC). In some types of 
cancers such as ESCC, patients with high expression of 
MINA53 had shorter survival periods. MINA 
expression is also activated not only MYC but also by 
other factors, because there are lymphoma and lung 
cancer tissues where the expression of MYC is 
downregulated but the expression of MINA is elevated 
(Teye et al., 2007; Komiya et al., 2010). The expression 
of MINA is also activated and mineral dust in human 
alveolar macrophage and human lung cancer cell line, 
A549 (Zhange et al., 2005). 
Expression 
MINA is ubiquitously expressed. The expression of 
MINA is frequently increased in various types of 
human cancers. In mice, MINA expression is high in 
some non-neoplastic tissues, including spleen, thymus, 
colon and testis, but low in skeletal muscle, cerebellum, 
and seminal vesicle. In testis the expression of MINA is 
high in spermatogonia and mitotic prophase cells and 
weakly in early pachytene spermatocyte but absent in 
late pachytene spermatocytes (Tsuneoka et al., 2006). 
Localisation 
MINA is diffusely nucleoplasmic and some portion is 
accumulated in nucleolus (Tsuneoka et al., 2002). 
Function 
Specific inhibition of MINA expression suppressed cell 
proliferation in some cultured cell lines (Tsuneoka et 
al., 2002). Forced expression of MINA in NIH/3T3 
cells induces cell transformation, and MINA-
transfected NIH/3T3 clones produce tumor in nude 
mice (Komiya et al., 2010). Therefore, MINA has 
oncogenic potential. MINA is a nuclear protein and a 
member of the jumonji C (JmjC) protein family. Thus, 
MINA is suspected to hydroxylate some proteins to 
control gene expression, but its substrate is not clear. 
Gene activation: MINA regulates several genes which 
are also regulated by MYC. Genes regulated by MINA 
but not by MYC include HGF, EGFR, and IL6 
(Komiya et al., 2010). 
Gene suppression: Recently, MINA was identified as  
 
a genetic determinant of T(H)2 bias. MINA specifically  
binds to and represses the IL4 promoter. MINA 
overexpression in transgenic mice impaired IL4 
expression, whereas its knockdown in primary CD4(+) 
T cells led to IL4 de-repression. Therefore MINA 
controls helper T cell differentiation through an IL4-
regulatory pathway (Okamoto et al,. 2009). These 
findings suggest that MINA may play a role on 
carcinogenesis also in the field of cancer immunology. 
Ribosome biogenesis: MINA is accumulated in 
nucleolus (Tsuneoka et al., 2002). Immunolocalization 
studies revealed that MINA is highly concentrated in 
the granular component of nucleoli (Eilbracht et al., 
2005). MINA is a constituent of free preribosomal 
particles but is absent from cytoplasmic ribosomes. 
MINA interacts with various ribosomal proteins as well 
as with a distinct set of non-ribosomal nucleolar 
proteins. These results suggest that MINA is directly 
involved in ribosome biogenesis, most likely during the 
assembly process of preribosomal particles (Eilbracht 
et al., 2005). MINA was also suggested to be involved 
in ribosomal RNA transcription (Lu et al., 2009). 
Homology 
The primary sequence of MINA has similarity to 
nucleolar protein NO66, which also has a JmjC 
domain. The JmjC domain of MINA has 50% identity 
to that of NO66. In 2010, it was report that NO66 
directly interacts with Osterix (Osx), which is an 
osteoblast-specific transcription factor required for 
osteoblast differentiation and bone formation. NO66 
exhibits a JmjC-dependent histone demethylase 
activity, which is specific for both H3K4me and 
H3K36me in vitro and in vivo. It was suggested that 
interactions between NO66 and Osx regulate Osx-
target genes in osteoblasts by modulating histone 




Colon cancer, esophageal squamous cell carcinoma, 
gingival squamous cell carcinoma, subtypes of human 
lymphoma, renal cell carcinoma, neuroblastoma, 
gastric carcinoma, lung cancer and hepatoma. 
Disease 
MINA expression is elevated in several types of 
carcinomas. 
Prognosis 
MINA is preferentially expressed in some types of 
cancers with a poor prognosis, including esophageal 
squamous cell carcinoma, advanced  
renal cell carcinoma, neuroblastoma. The expression 
levels of MINA may be used as a prognositic marker in 
these cancers. On the other hand, elevated expression 
of MINA in lung cancer patients is associated with 
favorable prognosis. 










The expression of MINA is elevated in all the 
adenocarcinomas compared to adjacent non-neoplastic 
tissues, which shows little staining. MINA is expressed 
in all pathological grades of cancer as well as in the 
adenoma. Staining patterns of Ki-67, a biomarker for 
cell proliferation, are similar to those of MINA in most 
cases. While anti-Ki-67 antibody strongly stains some 
well-proliferating non-neoplastic cells including cells 
in the deeper part of the crypts and in lymphoid 
germinal centers, antibody to MINA rarely stained 
those cells. These results indicate that the elevated 
expression of MINA is a characteristic feature in colon 
cancer (Teye et al., 2004). 
Esophageal cancer 
Note 
The expression of MINA in tumors is increased 
compared with that in adjacent non-neoplastic tissues. 
MINA was highly expressed in more than 80% of 
specimens. Anti-MINA antibody stained tumors more 
efficiently than antibody against Ki-67, a cell 
proliferation biomarker, in some cancer specimens. 
Patients with high expression of MINA has shorter 
survival periods, whereas the expression level of Ki-67 
in ESCC shows no relationship to patient outcome 
(Tsuneoka et al., 2004). 
Primary gingival squamous cell 
carcinoma 
Note 
A significant correlation was found between the 
expression of MINA and that of Ki-67 in patients with 
gingival squamous cell carcinoma or dysplastic 
gingiva. No significant correlation was noted between 
the expression of MINA or Ki-67 and prognostic 
factors such as the degree of differentiation, lymph 
node metastasis, stage, and tumor diameter (Kuratomi 
et al., 2006). 
Lymphoma 
Note 
Although MINA expression is not prominent in 
lymphoma in general, it is related to tumor progression 
of B cell lymphoma (Teye et al., 2007). 
Renal cell carcinoma (RCC) 
Note 
MINA is expressed in the nuclei of tumor cells and 
tubular nuclei of normal renal tissue.  
The expression level of MINA is significantly higher in 
patients with poor prognostic factors  
(stage IV, MVI-positive, and sarcomatoid RCC, and 
high Ki-67 LI). The prognosis of high MINA-
expressing tumors was significantly poorer than that of 
non-MINA-high tumors (Ishizaki et al., 2007). 
Neuroblastoma 
Note 
Surgically obtained neuroblastoma specimens were 
immunohistochemically stained to determine the 
MINA and Cap43 expression levels. A significant 
relationship was found between MINA and Ki-67, 
between MINA and neurotrophic tyrosine kinase, 
receptor, type 1 (TrkA), and between Cap43 and TrkA. 
The prognosis is significantly favorable in the Cap43 
high-expression cases, whereas it is significantly poor 




Elevated expression of MINA was observed in 91.1% 
of the gastric carcinomas. No significant associations 
were found between MINA and clinicopathological 
characteristics such as sex, age, histological 
differentiation, distant metastasis and lymph node 
metastasis. However, there was a significant 
association with depth of invasion and TMN stage. 
MINA expression was positively associated with a 
proliferation marker, PCNA, level (Zhang et al., 2008). 
Lung cancers 
Note 
The expression of MINA is elevated in lung cancer 
tissues (Lu et al., 2009; Komiya et al., 2010). The 
overexpression of MINA is an early event in lung 
cancer occurence (Lu et al., 2009; Komiya et al., 2010). 
Further, patients with negative staining for MINA has 
shorter survival than patients with positive staining for 
MINA, especially in stage I or with squamous cell 
carcinoma. These results suggest that overexpression of 
MINA in lung cancer patients is associated with 
favorable prognosis (Komiya et al., 2009). MINA may 
inhibit lung cancer cell invasion (Komiya et al., 2009). 
Hepatoma 
Note 
MINA is diffusely expressed in the nuclei of cancer 
cells in the tumor nodule, and is often strong at the 
periphery of tumor nodules. MINA expression is higher 
in poorly differentiated hepatocellular carcinoma 
(HCC) than in well-differentiated HCC, and there is 
significant relationship between MINA expression and 
histological grade. The high MINA expression is 
associated with high expression of a proliferation 
marker, antibody to Ki-67. MINA expression is high in 
the tumors of > 2 cm of diameter than in ≤ 2 cm 
(Ogasawara et al., 2010 in press). 
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